ORPHA:65759
Carpenter syndrome
Also known as: ACPS2 · Acrocephalopolysyndactyly type 2
Publications
1,451
Trials
0
Interventional, condition-specific
Researchers
1,196
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
A rare syndromic craniosynostosis with variable phenotypic expression characterized by craniosynostosis, , distinctive facies, abnormalities of the fingers and toes (brachydactyly, polydactyly and syndactyly), short stature, heart disease, skeletal defects, obesity, genital abnormalities and umbilical hernia.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019012
- UMLS:C1275078
- NCIT:C98873
Additional Mondo synonyms (4)
Carpenter 's syndrome · acrocephalopolysyndactyly type 2 · acrocephalopolysyndactyly type II · type II Acrocephalopolysyndactyly
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,451 matched papers (881 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
1,451
1,451 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
1,451 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
881 in the last 10 years · low confidence
Phrase hits: 1,451 · MeSH hits: 0
Who's working on it?
1,196
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Liu J4 papers · 2025
Institute of Blood Transfusion, Guangzhou Blood Centre, Luyuan Road 31, Guangzhou, Guangdong, China.
Papers in Europe PMC - 02Wang Y4 papers · 2026
Department of Cardiovascular Surgery, West China Hospital/West China School of Nursing, Sichuan University, Chengdu, Sichuan, China.
Papers in Europe PMC - 03Bossolasco P3 papers · 2026
Department of Neuroscience - Laboratory of Neuroscience , ,
Papers in Europe PMC - 04Chen Y3 papers · 2026
Institute of Blood Transfusion, Guangzhou Blood Centre, Luyuan Road 31, Guangzhou, Guangdong, China.
Papers in Europe PMC - 05Coraci D3 papers · 2024
Department of Neuroscience, Section of Rehabilitation, University of Padua, Padua, Italy.
Papers in Europe PMC - 06Hor CHH3 papers · 2025
Neuroscience Academic Clinical Programme, Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore.
Papers in Europe PMC - 07Invernizzi S3 papers · 2026
Department of Medical Biotechnology and Translational Medicine, Università degli Studi di Milano , ,
Papers in Europe PMC - 08Liu L3 papers · 2026
Department of Hand Surgery, Beijing Ji Shui Tan Hospital, Beijing, China.
Papers in Europe PMC - 09Magri S3 papers · 2026
Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta , ,
Papers in Europe PMC - 10Padua L3 papers · 2024
Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
low confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Carpenter syndrome" OR "ACPS2" OR "Acrocephalopolysyndactyly type 2" OR "Carpenter 's syndrome" OR "acrocephalopolysyndactyly type II" OR "type II Acrocephalopolysyndactyly"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Carpenter syndrome" OR "ACPS2" OR "Acrocephalopolysyndactyly type 2" OR "Carpenter 's syndrome" OR "acrocephalopolysyndactyly type II" OR "type II Acrocephalopolysyndactyly"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1451) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T01:19:41.590Z